J Gynecol Oncol.  2015 Oct;26(4):343-349. 10.3802/jgo.2015.26.4.343.

Controversies in borderline ovarian tumors

• Seong SJ
• Kim DH
• Kim MK
• Song T

• KMID: 2345926
• DOI: http://doi.org/10.3802/jgo.2015.26.4.343

Abstract

Borderline ovarian tumors (BOTs) represent about 15% to 20% of all ovarian malignancies and differ from invasive ovarian cancers (IOCs) by many characters. Historically, standard management of BOT is peritoneal washing cytology, hysterectomy, bilateral salpingo-oophorectomy, omentectomy, complete peritoneal resection of macroscopic lesions; in case of mucinous BOTs, appendectomy should be performed. Because BOTs are often diagnosed at earlier stage, in younger age women and have better prognosis, higher survival rate than IOCs, fertility-sparing surgery is one of the option to preserve childbearing capacity. The study of such conservative surgery is being released, and still controversial. After surgery, pregnancy and ovarian induction followed by in vitro fertilization are also significant issues. In surgery, laparoscopic technique can be used by a gynecologic oncology surgeon. So far postoperative chemotherapy, radiotherapy and hormone therapy are not recommended. We will discuss controversial issues of BOTs on this review and present the outline of the management of BOTs.

Keyword

Borderline Ovarian Tumors; Data Collection; Fertility; Management

MeSH Terms

Biopsy
Chemotherapy, Adjuvant
Female
Humans
Infertility, Female/prevention & control
Intraoperative Care/methods
Laparoscopy/methods
Laparotomy/methods
Neoplasm Recurrence, Local/therapy
Neoplasm Staging
Organ Sparing Treatments/methods
Ovarian Neoplasms/pathology/*therapy
Ovary/*pathology
Precancerous Conditions/pathology/therapy

Reference

1. Sutton GP. Ovarian tumors of low malignant potential. In : Rubin SC, Sutton GP, editors. Ovarian cancer. 2nd ed. Philadelphia: Lippincott Williams & Wilkins;2001. p. 399–417.

2. Katsube Y, Berg JW, Silverberg SG. Epidemiologic pathology of ovarian tumors: a histopathologic review of primary ovarian neoplasms diagnosed in the Denver Standard Metropolitan Statistical Area, 1 July-31 December 1969 and 1 July-31 December 1979. Int J Gynecol Pathol. 1982; 1:3–16.

3. Skirnisdottir I, Garmo H, Wilander E, Holmberg L. Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer. 2008; 123:1897–1901.

4. Sherman ME, Berman J, Birrer MJ, Cho KR, Ellenson LH, Gorstein F, et al. Current challenges and opportunities for research on borderline ovarian tumors. Hum Pathol. 2004; 35:961–970.

5. Bjorge T, Engeland A, Hansen S, Trope CG. Trends in the incidence of ovarian cancer and borderline tumours in Norway, 1954-1993. Int J Cancer. 1997; 71:780–786.

6. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95:Suppl 1. S161–S192.

7. Song T, Lee YY, Choi CH, Kim TJ, Lee JW, Bae DS, et al. Histologic distribution of borderline ovarian tumors worldwide: a systematic review. J Gynecol Oncol. 2013; 24:44–51.

8. Park JY, Kim DY, Kim JH, Kim YM, Kim KR, Kim YT, et al. Micropapillary pattern in serous borderline ovarian tumors: does it matter? Gynecol Oncol. 2011; 123:511–516.

9. Smith Sehdev AE, Sehdev PS, Kurman RJ. Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases. Am J Surg Pathol. 2003; 27:725–736.

10. Boger-Megiddo I, Weiss NS. Histologic subtypes and laterality of primary epithelial ovarian tumors. Gynecol Oncol. 2005; 97:80–83.

11. Patrono MG, Minig L, Diaz-Padilla I, Romero N, Rodriguez Moreno JF, Garcia-Donas J. Borderline tumours of the ovary, current controversies regarding their diagnosis and treatment. Ecancermedicalscience. 2013; 7:379.

12. Lalwani N, Shanbhogue AK, Vikram R, Nagar A, Jagirdar J, Prasad SR. Current update on borderline ovarian neoplasms. AJR Am J Roentgenol. 2010; 194:330–336.

13. Sherman ME, Mink PJ, Curtis R, Cote TR, Brooks S, Hartge P, et al. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer. 2004; 100:1045–1052.

14. Morice P. Borderline tumours of the ovary and fertility. Eur J Cancer. 2006; 42:149–158.

15. Burger CW, Prinssen HM, Baak JP, Wagenaar N, Kenemans P. The management of borderline epithelial tumors of the ovary. Int J Gynecol Cancer. 2000; 10:181–197.

16. Trope C, Davidson B, Paulsen T, Abeler VM, Kaern J. Diagnosis and treatment of borderline ovarian neoplasms "the state of the art". Eur J Gynaecol Oncol. 2009; 30:471–482.

17. Seidman JD, Cho KR, Ronnett BM, Kurman RJ. Surface epithelial tumors of the ovary. In : Kurman RJ, Ellenson LH, Ronnett BM, editors. Blaustein's pathology of the female genital tract. 6th ed. New York: Springer Science Business Medica;2011. p. 679–784.

18. du Bois A, Ewald-Riegler N, du Bois O, Harter P. Borderline tumors of the ovary: a systematic review. Geburtshilfe Frauenheilkd. 2009; 69:807–833.

19. Tempfer CB, Polterauer S, Bentz EK, Reinthaller A, Hefler LA. Accuracy of intraoperative frozen section analysis in borderline tumors of the ovary: a retrospective analysis of 96 cases and review of the literature. Gynecol Oncol. 2007; 107:248–252.

20. Gotlieb WH, Chetrit A, Menczer J, Hirsh-Yechezkel G, Lubin F, Friedman E, et al. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. Gynecol Oncol. 2005; 97:780–783.

21. Fauvet R, Boccara J, Dufournet C, David-Montefiore E, Poncelet C, Darai E. Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study. Cancer. 2004; 100:1145–1151.

22. Ahmed AS, Lawton FG. Borderline ovarian tumours: current concepts and management. Rev Gynaecol Pract. 2005; 5:139–151.

23. Camatte S, Morice P, Thoury A, Fourchotte V, Pautier P, Lhomme C, et al. Impact of surgical staging in patients with macroscopic "stage I" ovarian borderline tumours: analysis of a continuous series of 101 cases. Eur J Cancer. 2004; 40:1842–1849.

24. Vasconcelos I, de Sousa Mendes M. Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk. Eur J Cancer. 2015; 51:620–631.

25. Koskas M, Uzan C, Gouy S, Pautier P, Lhomme C, Haie-Meder C, et al. Prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma). Ann Surg Oncol. 2011; 18:40–48.

26. Poncelet C, Fauvet R, Boccara J, Darai E. Recurrence after cystectomy for borderline ovarian tumors: results of a French multicenter study. Ann Surg Oncol. 2006; 13:565–571.

27. Lim-Tan SK, Cajigas HE, Scully RE. Ovarian cystectomy for serous borderline tumors: a follow-up study of 35 cases. Obstet Gynecol. 1988; 72:775–781.

28. Lin PS, Gershenson DM, Bevers MW, Lucas KR, Burke TW, Silva EG. The current status of surgical staging of ovarian serous borderline tumors. Cancer. 1999; 85:905–911.

29. Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Mangioni C. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol. 2001; 19:2658–2664.

30. Uzan C, Kane A, Rey A, Gouy S, Duvillard P, Morice P. Outcomes after conservative treatment of advanced-stage serous borderline tumors of the ovary. Ann Oncol. 2010; 21:55–60.

31. Trillsch F, Mahner S, Ruetzel J, Harter P, Ewald-Riegler N, Jaenicke F, et al. Clinical management of borderline ovarian tumors. Expert Rev Anticancer Ther. 2010; 10:1115–1124.

32. Fischerova D, Franchi D, Testa A, Valentin LI, Savelli L, Lissoni A, et al. OC01.03: Ultrasound in diagnosis of new and recurrent borderline ovarian tumors. Ultrasound Obstet Gynecol. 2010; 36:Suppl 1. 1–2.

33. Desfeux P, Camatte S, Chatellier G, Blanc B, Querleu D, Lecuru F. Impact of surgical approach on the management of macroscopic early ovarian borderline tumors. Gynecol Oncol. 2005; 98:390–395.

34. Crispens MA, Bodurka D, Deavers M, Lu K, Silva EG, Gershenson DM. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol. 2002; 99:3–10.

35. Kehoe S, Powell J. Long-term follow-up of women with borderline ovarian tumors. Int J Gynaecol Obstet. 1996; 53:139–143.

36. Morice P, Camatte S, El Hassan J, Pautier P, Duvillard P, Castaigne D. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertil Steril. 2001; 75:92–96.

37. Romagnolo C, Gadducci A, Sartori E, Zola P, Maggino T. Management of borderline ovarian tumors: results of an Italian multicenter study. Gynecol Oncol. 2006; 101:255–260.

38. Gotlieb WH, Flikker S, Davidson B, Korach Y, Kopolovic J, Ben-Baruch G. Borderline tumors of the ovary: fertility treatment, conservative management, and pregnancy outcome. Cancer. 1998; 82:141–146.

39. Maneo A, Vignali M, Chiari S, Colombo A, Mangioni C, Landoni F. Are borderline tumors of the ovary safely treated by laparoscopy? Gynecol Oncol. 2004; 94:387–392.

40. Donnez J, Munschke A, Berliere M, Pirard C, Jadoul P, Smets M, et al. Safety of conservative management and fertility outcome in women with borderline tumors of the ovary. Fertil Steril. 2003; 79:1216–1221.

41. Salomon LJ, Lhomme C, Pautier P, Duvillard P, Morice P. Safety of simple cystectomy in patients with unilateral mucinous borderline tumors. Fertil Steril. 2006; 85:1510.e1–1510.e4.

42. van Leeuwen FE, Klip H, Mooij TM, van de, Lambalk CB, Kortman M, et al. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod. 2011; 26:3456–3465.

43. Fauvet R, Poncelet C, Boccara J, Descamps P, Fondrinier E, Darai E. Fertility after conservative treatment for borderline ovarian tumors: a French multicenter study. Fertil Steril. 2005; 83:284–290.

44. Oh S, Kim R, Lee YK, Kim JW, Park NH, Song YS. Clinicopathological aspects of patients with recurrence of borderline ovarian tumors. Obstet Gynecol Sci. 2015; 58:98–105.

45. Trope C, Kaern J, Vergote IB, Kristensen G, Abeler V. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. Gynecol Oncol. 1993; 51:236–243.

46. Deffieux X, Morice P, Camatte S, Fourchotte V, Duvillard P, Castaigne D. Results after laparoscopic management of serous borderline tumor of the ovary with peritoneal implants. Gynecol Oncol. 2005; 97:84–89.

47. Vergote I, Marquette S, Amant F, Berteloot P, Neven P. Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma. Int J Gynecol Cancer. 2005; 15:776–779.

48. Camatte S, Morice P, Atallah D, Thoury A, Pautier P, Lhomme C, et al. Clinical outcome after laparoscopic pure management of borderline ovarian tumors: results of a series of 34 patients. Ann Oncol. 2004; 15:605–609.

49. Morice P, Camatte S, Rey A, Atallah D, Lhomme C, Pautier P, et al. Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol. 2003; 14:592–598.

50. Vasconcelos I, Olschewski J, Braicu I, Sehouli J. Limited efficacy of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors. Eur J Obstet Gynecol Reprod Biol. 2015; 186:26–33.

51. Vasconcelos I, Olschewski J, Braicu I, Sehouli J. A meta-analysis on the impact of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors with invasive implants. Oncologist. 2015; 20:151–158.

52. Abu-Jawdeh GM, Jacobs TW, Niloff J, Cannistra SA. Estrogen receptor expression is a common feature of ovarian borderline tumors. Gynecol Oncol. 1996; 60:301–307.

53. Sallum LF, Sarian LO, Lucci De, Vassallo J, Soares FA, Pinto GA, et al. Survival of women with ovarian carcinomas and borderline tumors is not affected by estrogen and progesterone receptor status. J Gynecol Oncol. 2013; 24:167–176.

54. Lee EJ, Deavers MT, Hughes JI, Lee JH, Kavanagh JJ. Metastasis to sigmoid colon mucosa and submucosa from serous borderline ovarian tumor: response to hormone therapy. Int J Gynecol Cancer. 2006; 16:Suppl 1. 295–299.

55. Fischerova D, Zikan M, Dundr P, Cibula D. Diagnosis, treatment, and follow-up of borderline ovarian tumors. Oncologist. 2012; 17:1515–1533.